Sign inCreate account

Report workspace tools

NCT00357760COMPLETEDanonymous

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma

Sponsor

Source record

National Cancer Institute (NCI)

Phase

Source record

PHASE2

Modality

AI-normalized

protein therapy

Target

AI-normalized

VEGF Trap

Indication / condition

AI-normalized

Metastatic Renal Cell Carcinoma

Intervention

Source record

VEGF Trap

Source & freshness

Source record

NCT ID

NCT00357760

Original source

ClinicalTrials.gov

Source last updated

Jun 23, 2017

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00357760

Title

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma

Sponsor

National Cancer Institute (NCI)

Status

COMPLETED

Phase

PHASE2

Condition raw

Metastatic Renal Cell Carcinoma

Condition normalized

Metastatic Renal Cell Carcinoma

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

VEGF Trap

Target normalized

VEGF Trap

Interventions

VEGF Trap

Public preview

Source record

This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed with surgery (unresectable). Ziv-aflibercept may stop the growth of kidney cancer by blocking blood flow to the tumor.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00357760

Status

COMPLETED

Phase

PHASE2

Sponsor

National Cancer Institute (NCI)

Executive brief

Investment-Ready Snapshot

This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed with surgery (unresectable). Ziv-aflibercept may stop the growth of kidney cancer by blocking blood flow to the tumor.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 23, 2017
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00357760

Indication

Metastatic Renal Cell Carcinoma

Modality

protein therapy

Target

VEGF Trap

Intervention

VEGF Trap

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.